Pub Date : 2025-02-07DOI: 10.4274/mirt.galenos.2024.37929
Manale Otmani, Salah Oueriagli Nabih, Omar Ait Sahel, Yassir Benameur, Abderrahim Doudouh
Neoplastic infiltration of the omentum is mostly caused by metastatic ovarian, gastric, colon, or pancreatic cancer. Lymphomatous infiltration of the omentum is rare because the omentum lacks a lymphoid component. To date, lymphomatous involvement of the omentum has only been reported in patients with non-Hodgkin lymphoma. Peritoneal lymphomatosis remains a rare presentation of malignant lymphoma characterized by diffuse peritoneal lesions and is frequently accompanied by ascites and mesenteric lesions. In this review, we aimed to illustrate the case of a 72 year old mal patient diagnosed with aggressive large B-cell lymphoma, adressed for initial extension assessment in whom 18F-fluorodeoxyglucose positron emission tomograph/computed tomography found unusual omental and mesenteric involvement.
{"title":"Omental Cake in Non-Hodgkin's Disease: <sup>18</sup>F-FDG PET-CT Findings.","authors":"Manale Otmani, Salah Oueriagli Nabih, Omar Ait Sahel, Yassir Benameur, Abderrahim Doudouh","doi":"10.4274/mirt.galenos.2024.37929","DOIUrl":"10.4274/mirt.galenos.2024.37929","url":null,"abstract":"<p><p>Neoplastic infiltration of the omentum is mostly caused by metastatic ovarian, gastric, colon, or pancreatic cancer. Lymphomatous infiltration of the omentum is rare because the omentum lacks a lymphoid component. To date, lymphomatous involvement of the omentum has only been reported in patients with non-Hodgkin lymphoma. Peritoneal lymphomatosis remains a rare presentation of malignant lymphoma characterized by diffuse peritoneal lesions and is frequently accompanied by ascites and mesenteric lesions. In this review, we aimed to illustrate the case of a 72 year old mal patient diagnosed with aggressive large B-cell lymphoma, adressed for initial extension assessment in whom <sup>18</sup>F-fluorodeoxyglucose positron emission tomograph/computed tomography found unusual omental and mesenteric involvement.</p>","PeriodicalId":44681,"journal":{"name":"Molecular Imaging and Radionuclide Therapy","volume":"34 1","pages":"79-81"},"PeriodicalIF":0.9,"publicationDate":"2025-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11827524/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143366284","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-02-07DOI: 10.4274/mirt.galenos.2024.48264
Huimin Li, Zhehao Lyu
Primary liposarcoma of the lung is extremely rare. To date, only 24 cases have been reported in the English literature. Herein, we present a case of well-differentiated pulmonary liposarcoma that was misdiagnosed as teratoma on positron emission tomography/computed tomography (CT) and contrast-enhanced CT. Radical surgery with left superior lobectomy and mediastinal lymph node dissection were performed. The patient experienced recurrence and distant metastases 33 months after surgery. He was alive at the time of writing this report (36 months postoperatively). To our knowledge, this is the first case report of pulmonary well-differentiated liposarcoma.
{"title":"Primary Pulmonary Liposarcoma: A Case Report.","authors":"Huimin Li, Zhehao Lyu","doi":"10.4274/mirt.galenos.2024.48264","DOIUrl":"10.4274/mirt.galenos.2024.48264","url":null,"abstract":"<p><p>Primary liposarcoma of the lung is extremely rare. To date, only 24 cases have been reported in the English literature. Herein, we present a case of well-differentiated pulmonary liposarcoma that was misdiagnosed as teratoma on positron emission tomography/computed tomography (CT) and contrast-enhanced CT. Radical surgery with left superior lobectomy and mediastinal lymph node dissection were performed. The patient experienced recurrence and distant metastases 33 months after surgery. He was alive at the time of writing this report (36 months postoperatively). To our knowledge, this is the first case report of pulmonary well-differentiated liposarcoma.</p>","PeriodicalId":44681,"journal":{"name":"Molecular Imaging and Radionuclide Therapy","volume":"34 1","pages":"73-75"},"PeriodicalIF":0.9,"publicationDate":"2025-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11827523/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143366290","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
A Chemoport is frequently utilized in oncological patients for administering chemotherapy. However, inadequate care can lead to various infectious and non-infectious complications. Infection commonly presents as a local infection that can lead to life-threatening septicemia. Early diagnosis and intervention are necessary to reduce morbidity and mortality. We report a patient with breast cancer who underwent 18F-fluorodeoxyglucose positron (18F-FDG) positron emission tomography/computed tomography (PET/CT) due to suspicion of metastatic disease. 18F-FDG-PET/CT revealed pyomyositis involving multiple skeletal muscles and septic emboli in the lungs and identified the chemoport as a possible source of infection. The infection source was confirmed and the patient responded to anti-microbiological therapy.
{"title":"Pyomyositis as Presentation of Chemoport-related Infection in Breast Carcinoma: <sup>18</sup>F-FDG PET/CT Findings.","authors":"Vijay Singh, Dinesh Srivastava, Neha Kotarya, Manish Ora, Sanjay Gambhir","doi":"10.4274/mirt.galenos.2024.46547","DOIUrl":"10.4274/mirt.galenos.2024.46547","url":null,"abstract":"<p><p>A Chemoport is frequently utilized in oncological patients for administering chemotherapy. However, inadequate care can lead to various infectious and non-infectious complications. Infection commonly presents as a local infection that can lead to life-threatening septicemia. Early diagnosis and intervention are necessary to reduce morbidity and mortality. We report a patient with breast cancer who underwent <sup>18</sup>F-fluorodeoxyglucose positron (<sup>18</sup>F-FDG) positron emission tomography/computed tomography (PET/CT) due to suspicion of metastatic disease. <sup>18</sup>F-FDG-PET/CT revealed pyomyositis involving multiple skeletal muscles and septic emboli in the lungs and identified the chemoport as a possible source of infection. The infection source was confirmed and the patient responded to anti-microbiological therapy.</p>","PeriodicalId":44681,"journal":{"name":"Molecular Imaging and Radionuclide Therapy","volume":"34 1","pages":"76-78"},"PeriodicalIF":0.9,"publicationDate":"2025-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11827528/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143366306","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Objectives: This study aimed to evaluate the potential efficacy of 68Ga-fibroblast activation protein inhibitor (FAPi) positron emission tomography/computed tomography (PET/CT) for detecting, staging, and restaging digestive system malignancies that are 18F-fluorodeoxyglucose (18F-FDG) negative or show equivocal 18F-FDG uptake.
Methods: We conducted a prospective analysis of 30 patients with pathologically confirmed primary tumors or metastases of the digestive system. Participants underwent 68Ga-FAPi PET/CT and 18F-FDG PET/CT imaging for staging or restaging purposes within the same week. The efficacy of 68Ga-FAPi PET/CT was assessed by comparing its ability to detect lesions and influence disease staging with that of 18F-FDG PET/CT.
Results: 68Ga-FAPi PET/CT imaging was performed in 30 patients with 18F-FDG-negative or indeterminate lesions. Of the 30 patients, 23 had gastric cancer and 7 had colorectal cancer. Among all patients, histopathological diagnosis of signet ring cell carcinoma was present in 15 (50%) patients. Primary tumor or local recurrence was detected in 19 (63%) patients, lymph node metastasis in 8 (27%) patients, visceral metastasis in 4 (13%) patients, peritoneal metastasis in 14 (47%) patients, and bone metastasis in 3 (10%) patients on 68Ga-FAPi PET/CT images. All patients underwent histopathological confirmation on 68Ga-FAPi PET/CT images. The disease stage was upgraded in 20 patients (67%) after 68Ga-FAPi PET/CT imaging. Of the 20 patients, 12 had no evidence of recurrence or metastasis on 18F-FDG PET/CT.
Conclusion: Based on our study, 68Ga-FAPi PET/CT alters the disease stage in the majority of gastrointestinal malignancies with negative or equivocal 18F-FDG PET/CT findings. 68Ga-FAPi PET/CT appears to be effective in both staging and restaging of gastrointestinal malignancies, such as signet-ring cell carcinomas of the stomach that frequently show low 18F-FDG -avidity.
{"title":"Impact of <sup>68</sup>Ga-FAPi PET/CT on Staging or Restaging Digestive System Tumors in Patients with Negative or Equivocal <sup>18</sup>F-FDG PET/CT Findings.","authors":"Nalan Alan Selçuk, Gamze Beydağı, Kaan Akçay, Emre Demirci, Ayşegül Görmez, Bala Başak Öven, Serkan Çelik, Fatma Şen, Özge Kapar, Levent Kabasakal","doi":"10.4274/mirt.galenos.2024.50470","DOIUrl":"10.4274/mirt.galenos.2024.50470","url":null,"abstract":"<p><strong>Objectives: </strong>This study aimed to evaluate the potential efficacy of <sup>68</sup>Ga-fibroblast activation protein inhibitor (FAPi) positron emission tomography/computed tomography (PET/CT) for detecting, staging, and restaging digestive system malignancies that are <sup>18</sup>F-fluorodeoxyglucose (<sup>18</sup>F-FDG) negative or show equivocal <sup>18</sup>F-FDG uptake.</p><p><strong>Methods: </strong>We conducted a prospective analysis of 30 patients with pathologically confirmed primary tumors or metastases of the digestive system. Participants underwent <sup>68</sup>Ga-FAPi PET/CT and <sup>18</sup>F-FDG PET/CT imaging for staging or restaging purposes within the same week. The efficacy of <sup>68</sup>Ga-FAPi PET/CT was assessed by comparing its ability to detect lesions and influence disease staging with that of <sup>18</sup>F-FDG PET/CT.</p><p><strong>Results: </strong><sup>68</sup>Ga-FAPi PET/CT imaging was performed in 30 patients with <sup>18</sup>F-FDG-negative or indeterminate lesions. Of the 30 patients, 23 had gastric cancer and 7 had colorectal cancer. Among all patients, histopathological diagnosis of signet ring cell carcinoma was present in 15 (50%) patients. Primary tumor or local recurrence was detected in 19 (63%) patients, lymph node metastasis in 8 (27%) patients, visceral metastasis in 4 (13%) patients, peritoneal metastasis in 14 (47%) patients, and bone metastasis in 3 (10%) patients on <sup>68</sup>Ga-FAPi PET/CT images. All patients underwent histopathological confirmation on <sup>68</sup>Ga-FAPi PET/CT images. The disease stage was upgraded in 20 patients (67%) after <sup>68</sup>Ga-FAPi PET/CT imaging. Of the 20 patients, 12 had no evidence of recurrence or metastasis on <sup>18</sup>F-FDG PET/CT.</p><p><strong>Conclusion: </strong>Based on our study, <sup>68</sup>Ga-FAPi PET/CT alters the disease stage in the majority of gastrointestinal malignancies with negative or equivocal <sup>18</sup>F-FDG PET/CT findings. <sup>68</sup>Ga-FAPi PET/CT appears to be effective in both staging and restaging of gastrointestinal malignancies, such as signet-ring cell carcinomas of the stomach that frequently show low <sup>18</sup>F-FDG -avidity.</p>","PeriodicalId":44681,"journal":{"name":"Molecular Imaging and Radionuclide Therapy","volume":"34 1","pages":"31-37"},"PeriodicalIF":0.9,"publicationDate":"2025-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11827526/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143366076","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
A 39-year-old woman presented with left neck masses for 4 months and epiphora of the left eye for 3 weeks. Ultrasonography revealed a mass in the left parotid gland and multiple cervical lymph nodes. Biopsy of the mass in the left parotid gland revealed infiltrating ductal carcinoma. 18F-fluorodeoxyglucose positron emission tomography/computed tomography scan was undertaken, which showed a mass in the left parotid gland and multiple cervical lymph nodes with high metabolism. A nodule in the left nasolacrimal duct with high metabolism was observed. The nodule was surgically removed and pathologically confirmed as metastatic parotid ductal carcinoma.
{"title":"Nasolacrimal Metastasis from Parotid Ductal Carcinoma Detected by <sup>18</sup>F-FDG PET/CT.","authors":"Kexia Fang, Jianqiang Li, Guodong Feng, Xiang Guo, Yumin Zheng","doi":"10.4274/mirt.galenos.2024.46667","DOIUrl":"10.4274/mirt.galenos.2024.46667","url":null,"abstract":"<p><p>A 39-year-old woman presented with left neck masses for 4 months and epiphora of the left eye for 3 weeks. Ultrasonography revealed a mass in the left parotid gland and multiple cervical lymph nodes. Biopsy of the mass in the left parotid gland revealed infiltrating ductal carcinoma. <sup>18</sup>F-fluorodeoxyglucose positron emission tomography/computed tomography scan was undertaken, which showed a mass in the left parotid gland and multiple cervical lymph nodes with high metabolism. A nodule in the left nasolacrimal duct with high metabolism was observed. The nodule was surgically removed and pathologically confirmed as metastatic parotid ductal carcinoma.</p>","PeriodicalId":44681,"journal":{"name":"Molecular Imaging and Radionuclide Therapy","volume":"34 1","pages":"82-84"},"PeriodicalIF":0.9,"publicationDate":"2025-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11827531/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143366207","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-02-07DOI: 10.4274/mirt.galenos.2024.37431
Ahmet Tanyeri, Rıdvan Akbulut, Emir Hüseyin Nevai, Yakup Yürekli
Objectives: Positron emission tomography/computed tomography (PET/CT) and magnetic resonance imaging (MRI) are widely used in the diagnosis and follow-up of liver metastases. Both modalities provide anatomical and functional information and have advantages and disadvantages. The objective of this study was to investigate the correlation between apparent diffusion coefficient (ADC) and standardized uptake value (SUV) values in metastatic liver lesions.
Methods: Abdominal magnetic resonance (MR) scans performed between April 2021 and 2024 using the 3T MR scanner were retrospectively evaluated. Thirty-three patients with liver metastases, less than one month between magnetic resonance imaging (MRI) and PET/CT, no treatment during this period, and lesions larger than 1 cm were included in the study. In each MRI scan, an index lesion was selected for ADC measurement. The radiologist and nuclear medicine specialist measured the same index lesion without the patient being informed of the results.
Results: The mean age of the 33 patients was 59±12 years, with 17 (51%) men and 16 (49%) women. The mean size of the index lesions was 27±9 mm. In MRI, mean ADCmin: (0.54±0.2) ×10-3mm2/s; ADCmean: (1.02±0.2) ×10-3mm2/s; ADCmax: (1.48±0.44) ×10-3mm2/s; and region of interest area was calculated as 6±4.6 cm2. In PET/CT, mean SUVmean: 5.8±3.3; SUVpeak: 6.8±4.3; SUVmax: 10.7±5.6; and metabolic tumor volume: 12.1 (7.4-20.7) cm3. No statistically significant correlation was found between ADC and SUV values.
Conclusion: There was no correlation between ADC and SUV values in liver metastases. Prospective studies with a large patient group are needed.
{"title":"Correlation of 3T Diffusion-weighted MRI and <sup>18</sup>F-FDG-PET/CT in Liver Metastases: SUV Versus ADC.","authors":"Ahmet Tanyeri, Rıdvan Akbulut, Emir Hüseyin Nevai, Yakup Yürekli","doi":"10.4274/mirt.galenos.2024.37431","DOIUrl":"10.4274/mirt.galenos.2024.37431","url":null,"abstract":"<p><strong>Objectives: </strong>Positron emission tomography/computed tomography (PET/CT) and magnetic resonance imaging (MRI) are widely used in the diagnosis and follow-up of liver metastases. Both modalities provide anatomical and functional information and have advantages and disadvantages. The objective of this study was to investigate the correlation between apparent diffusion coefficient (ADC) and standardized uptake value (SUV) values in metastatic liver lesions.</p><p><strong>Methods: </strong>Abdominal magnetic resonance (MR) scans performed between April 2021 and 2024 using the 3T MR scanner were retrospectively evaluated. Thirty-three patients with liver metastases, less than one month between magnetic resonance imaging (MRI) and PET/CT, no treatment during this period, and lesions larger than 1 cm were included in the study. In each MRI scan, an index lesion was selected for ADC measurement. The radiologist and nuclear medicine specialist measured the same index lesion without the patient being informed of the results.</p><p><strong>Results: </strong>The mean age of the 33 patients was 59±12 years, with 17 (51%) men and 16 (49%) women. The mean size of the index lesions was 27±9 mm. In MRI, mean ADC<sub>min</sub>: (0.54±0.2) ×10<sup>-3</sup>mm<sup>2</sup>/s; ADC<sub>mean</sub>: (1.02±0.2) ×10<sup>-3</sup>mm<sup>2</sup>/s; ADC<sub>max</sub>: (1.48±0.44) ×10<sup>-3</sup>mm<sup>2</sup>/s; and region of interest area was calculated as 6±4.6 cm<sup>2</sup>. In PET/CT, mean SUV<sub>mean</sub>: 5.8±3.3; SUV<sub>peak</sub>: 6.8±4.3; SUV<sub>max</sub>: 10.7±5.6; and metabolic tumor volume: 12.1 (7.4-20.7) cm<sup>3</sup>. No statistically significant correlation was found between ADC and SUV values.</p><p><strong>Conclusion: </strong>There was no correlation between ADC and SUV values in liver metastases. Prospective studies with a large patient group are needed.</p>","PeriodicalId":44681,"journal":{"name":"Molecular Imaging and Radionuclide Therapy","volume":"34 1","pages":"48-54"},"PeriodicalIF":0.9,"publicationDate":"2025-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11827527/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143366146","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-02-07DOI: 10.4274/mirt.galenos.2024.47135
Fulya Kaya, Halil Kömek, İbrahim Hakkı Dursun, Veysi Şenses, Cihan Gündoğan
A 57-year-old man diagnosed with a metastatic bladder tumor was initiated on pembrolizumab treatment. 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) imaging performed to evaluate treatment response showed numerical-dimensional and metabolic increase in the metastatic lesions. In the 18F-FDG PET/CT imaging performed 8 weeks later due to suspicion of pseudoprogression, a significant regression of the lesions was observed, and the patient was diagnosed with pseudoprogression. Pseudoprogression should be kept in mind when 18F-FDG PET/CT is performed after the use of immunotherapy, and evaluation with follow-up PET/CT is recommended to confirm that the patient has hyperprogression or pseudoprogression.
{"title":"Pseudoprogression Shown on <sup>18</sup>F-FDG PET/CT After Pembrolizumab Treatment in a Case of Metastatic Bladder Cancer.","authors":"Fulya Kaya, Halil Kömek, İbrahim Hakkı Dursun, Veysi Şenses, Cihan Gündoğan","doi":"10.4274/mirt.galenos.2024.47135","DOIUrl":"10.4274/mirt.galenos.2024.47135","url":null,"abstract":"<p><p>A 57-year-old man diagnosed with a metastatic bladder tumor was initiated on pembrolizumab treatment. <sup>18</sup>F-fluorodeoxyglucose (<sup>18</sup>F-FDG) positron emission tomography/computed tomography (PET/CT) imaging performed to evaluate treatment response showed numerical-dimensional and metabolic increase in the metastatic lesions. In the <sup>18</sup>F-FDG PET/CT imaging performed 8 weeks later due to suspicion of pseudoprogression, a significant regression of the lesions was observed, and the patient was diagnosed with pseudoprogression. Pseudoprogression should be kept in mind when <sup>18</sup>F-FDG PET/CT is performed after the use of immunotherapy, and evaluation with follow-up PET/CT is recommended to confirm that the patient has hyperprogression or pseudoprogression.</p>","PeriodicalId":44681,"journal":{"name":"Molecular Imaging and Radionuclide Therapy","volume":"34 1","pages":"70-72"},"PeriodicalIF":0.9,"publicationDate":"2025-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11827530/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143366301","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-02-07DOI: 10.4274/mirt.galenos.2024.78557
Özge Ulaş Babacan, Zekiye Hasbek, Hatice Terzi
Objectives: This study aimed to evaluate the relationship between the degree of bone marrow involvement, hematological parameters, and 18F-fluorodeoxyglucose (18F-FDG)-positron emission tomography/computed tomography (PET/CT) data in patients diagnosed with multiple myeloma.
Methods: A total of 71 patients [19 females, 52 males, mean age 67 (36-83) years] who were diagnosed with multiple myeloma between 2014 and 2021, had not received any treatment yet, and underwent 18F-FDG-PET/CT for staging were included in the study.
Results: No significant correlation was observed between bone marrow standardized uptake value (SUV)max and plasma cell infiltration (p=0.07). However, we found that patients with visually increased bone marrow counts also had higher plasma cell infiltration rates (p=0.037). No significant correlation was found between plasma cell infiltration rates and bone marrow SUVmax and systemic inflammatory index (SII) (p=0.187 and p=0.446, respectively). However, there was a significant correlation between the SUVmax of lytic lesions showing increased 18F-FDG uptake in bone and SII (p=0.025, r=0.330).
Conclusion: We believe that 18F-FDG PET/CT may be an advantage over bone marrow biopsy in the diagnosis and evaluation of multiple myeloma recurrence and may prevent repeated bone marrow biopsies.
{"title":"Relationship of Plasma Cell Infiltration Rates with <sup>18</sup>F-FDG PET/CT Data and Hematological Parameters in Multiple Myeloma.","authors":"Özge Ulaş Babacan, Zekiye Hasbek, Hatice Terzi","doi":"10.4274/mirt.galenos.2024.78557","DOIUrl":"10.4274/mirt.galenos.2024.78557","url":null,"abstract":"<p><strong>Objectives: </strong>This study aimed to evaluate the relationship between the degree of bone marrow involvement, hematological parameters, and <sup>18</sup>F-fluorodeoxyglucose (<sup>18</sup>F-FDG)-positron emission tomography/computed tomography (PET/CT) data in patients diagnosed with multiple myeloma.</p><p><strong>Methods: </strong>A total of 71 patients [19 females, 52 males, mean age 67 (36-83) years] who were diagnosed with multiple myeloma between 2014 and 2021, had not received any treatment yet, and underwent <sup>18</sup>F-FDG-PET/CT for staging were included in the study.</p><p><strong>Results: </strong>No significant correlation was observed between bone marrow standardized uptake value (SUV)<sub>max</sub> and plasma cell infiltration (p=0.07). However, we found that patients with visually increased bone marrow counts also had higher plasma cell infiltration rates (p=0.037). No significant correlation was found between plasma cell infiltration rates and bone marrow SUV<sub>max</sub> and systemic inflammatory index (SII) (p=0.187 and p=0.446, respectively). However, there was a significant correlation between the SUV<sub>max</sub> of lytic lesions showing increased <sup>18</sup>F-FDG uptake in bone and SII (p=0.025, r=0.330).</p><p><strong>Conclusion: </strong>We believe that <sup>18</sup>F-FDG PET/CT may be an advantage over bone marrow biopsy in the diagnosis and evaluation of multiple myeloma recurrence and may prevent repeated bone marrow biopsies.</p>","PeriodicalId":44681,"journal":{"name":"Molecular Imaging and Radionuclide Therapy","volume":"34 1","pages":"26-30"},"PeriodicalIF":0.9,"publicationDate":"2025-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11827519/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143366233","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-02-07DOI: 10.4274/mirt.galenos.2024.60566
Alper Özgür Karaçalıoğlu
{"title":"A Different Scintigraphic Perspective on the Systolic Function of the Left Ventricle-1.","authors":"Alper Özgür Karaçalıoğlu","doi":"10.4274/mirt.galenos.2024.60566","DOIUrl":"10.4274/mirt.galenos.2024.60566","url":null,"abstract":"","PeriodicalId":44681,"journal":{"name":"Molecular Imaging and Radionuclide Therapy","volume":"34 1","pages":"88-89"},"PeriodicalIF":0.9,"publicationDate":"2025-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11827517/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143366144","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Objectives: Delayed [68Ga]Ga-prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) images show reduced PSMA uptake in benign lesions and increased PSMA uptake in malignant lesions. This study investigated the efficacy of PRIMARY scoring on [68Ga]Ga-PSMA PET/CT images at standard versus delayed time points and assessed the potential added value of delayed imaging in PRIMARY scoring.
Methods: A total of 140 patients with biopsy results of International Society of Urological Pathology grade groups (ISUP) 1-2 who had standard (median 60 min) and delayed images (median 138 min) with [68Ga]Ga-PSMA PET/CT before radical prostatectomy were included. Results were confirmed in pathological reports. For diagnostic parameters, two experienced nuclear medicine physicians, who were blinded to clinical data, independently reviewed the images, and a third physician provided consensus in cases of disagreement. PRIMARY scoring was also conducted by four nuclear medicine physicians on both images, with a 1-month interval between assessments for intraobserver agreement analyses.
Results: The percentage of lesions scored as 1-2 in PRIMARY scoring decreased from 29% to 10% in delayed images compared with standard images, whereas lesions scored as 3-5 increased from 71% to 90%. Additionally, agreement between two experienced nuclear medicine physicians regarding scoring was 66% for standard imaging and 77% for delayed imaging. The number of patients with PRIMARY score 5 increased from 31 to 46 in delayed imaging. All patients were confirmed to have clinically significant prostate cancer (csPCa). Furthermore, no csPCa of ISUP grade 3 or higher was detected in patients with a delayed PRIMARY score (dPRIMARY). The sensitivity of standard PRIMARY scoring was 71%, which increased to 92% with dPRIMARY scoring, with a consistent positive predictive value of 87% for both. Intraobserver agreement Cohen's kappa values for all observers were higher for delayed images than for standard images. Inter-observer agreement, assessed by Fleiss kappa, was 0.47 and 0.52 for standard images in rounds 1 and 2, respectively, and 0.61 and 0.72 for delayed images, respectively.
Conclusion: Decreased background activity and increased primary tumor uptake in delayed images improved differentiation between primary tumors and benign lesions, leading to better primary tumor identification. Enhanced reliability was also observed in both intraobserver and interobserver assessments of delayed images.
目的:延迟[68Ga] ga -前列腺特异性膜抗原(PSMA)正电子发射断层扫描/计算机断层扫描(PET/CT)图像显示良性病变中PSMA摄取减少,恶性病变中PSMA摄取增加。本研究探讨了PRIMARY评分在标准时间点和延迟时间点对[68Ga]Ga-PSMA PET/CT图像的疗效,并评估了延迟成像在PRIMARY评分中的潜在附加价值。方法:共纳入140例活检结果符合国际泌尿外科学会分级组(ISUP) 1-2的患者,这些患者在根治性前列腺切除术前接受了[68Ga]Ga-PSMA PET/CT的标准图像(中位60分钟)和延迟图像(中位138分钟)。病理报告证实了这一结果。对于诊断参数,两名经验丰富的核医学医生,他们对临床数据不知情,独立审查图像,第三名医生在有分歧的情况下提供共识。四名核医学医生也对两幅图像进行了初级评分,评估间隔1个月进行观察者内一致性分析。结果:与标准图像相比,延迟图像中PRIMARY评分为1-2分的病变百分比从29%下降到10%,而3-5分的病变百分比从71%上升到90%。此外,两名经验丰富的核医学医生对标准成像评分的一致性为66%,延迟成像评分的一致性为77%。延迟成像中PRIMARY评分为5的患者从31例增加到46例。所有患者均确诊为临床显著性前列腺癌(csPCa)。此外,在延迟PRIMARY评分(dPRIMARY)的患者中未检测到ISUP 3级或更高级别的csPCa。标准PRIMARY评分的敏感性为71%,dPRIMARY评分的敏感性增加到92%,两者的一致阳性预测值为87%。观察者内部一致性Cohen’s kappa值对于延迟图像比标准图像更高。通过Fleiss kappa评估,第1轮和第2轮标准图像的观察者间一致性分别为0.47和0.52,延迟图像的观察者间一致性分别为0.61和0.72。结论:延迟图像中背景活动的减少和原发肿瘤摄取的增加提高了原发肿瘤与良性病变的区分,从而更好地识别原发肿瘤。在观察者内部和观察者之间对延迟图像的评估中也观察到增强的可靠性。
{"title":"Improved Accuracy and Reliability of PRIMARY Scoring Using Delayed [<sup>68</sup>Ga] Ga-PSMA PET/CT Imaging.","authors":"Kaan Akçay, Gamze Beydağı, Onur Erdem Şahin, Reşit Akyel, Elife Akgün, Özgül Ekmekçioğlu, Nalan Alan Selçuk, Türkay Toklu, Asiye Işın Doğan Ekici, Kayra Kapran, Levent Kabasakal","doi":"10.4274/mirt.galenos.2025.16023","DOIUrl":"10.4274/mirt.galenos.2025.16023","url":null,"abstract":"<p><strong>Objectives: </strong>Delayed [<sup>68</sup>Ga]Ga-prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) images show reduced PSMA uptake in benign lesions and increased PSMA uptake in malignant lesions. This study investigated the efficacy of PRIMARY scoring on [<sup>68</sup>Ga]Ga-PSMA PET/CT images at standard versus delayed time points and assessed the potential added value of delayed imaging in PRIMARY scoring.</p><p><strong>Methods: </strong>A total of 140 patients with biopsy results of International Society of Urological Pathology grade groups (ISUP) 1-2 who had standard (median 60 min) and delayed images (median 138 min) with [<sup>68</sup>Ga]Ga-PSMA PET/CT before radical prostatectomy were included. Results were confirmed in pathological reports. For diagnostic parameters, two experienced nuclear medicine physicians, who were blinded to clinical data, independently reviewed the images, and a third physician provided consensus in cases of disagreement. PRIMARY scoring was also conducted by four nuclear medicine physicians on both images, with a 1-month interval between assessments for intraobserver agreement analyses.</p><p><strong>Results: </strong>The percentage of lesions scored as 1-2 in PRIMARY scoring decreased from 29% to 10% in delayed images compared with standard images, whereas lesions scored as 3-5 increased from 71% to 90%. Additionally, agreement between two experienced nuclear medicine physicians regarding scoring was 66% for standard imaging and 77% for delayed imaging. The number of patients with PRIMARY score 5 increased from 31 to 46 in delayed imaging. All patients were confirmed to have clinically significant prostate cancer (csPCa). Furthermore, no csPCa of ISUP grade 3 or higher was detected in patients with a delayed PRIMARY score (dPRIMARY). The sensitivity of standard PRIMARY scoring was 71%, which increased to 92% with dPRIMARY scoring, with a consistent positive predictive value of 87% for both. Intraobserver agreement Cohen's kappa values for all observers were higher for delayed images than for standard images. Inter-observer agreement, assessed by Fleiss kappa, was 0.47 and 0.52 for standard images in rounds 1 and 2, respectively, and 0.61 and 0.72 for delayed images, respectively.</p><p><strong>Conclusion: </strong>Decreased background activity and increased primary tumor uptake in delayed images improved differentiation between primary tumors and benign lesions, leading to better primary tumor identification. Enhanced reliability was also observed in both intraobserver and interobserver assessments of delayed images.</p>","PeriodicalId":44681,"journal":{"name":"Molecular Imaging and Radionuclide Therapy","volume":"34 1","pages":"1-9"},"PeriodicalIF":0.9,"publicationDate":"2025-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11827525/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143366077","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}